Literature DB >> 35301454

Benefit of empagliflozin in acute heart failure.

Gregory B Lim1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35301454     DOI: 10.1038/s41569-022-00693-x

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.

Authors:  Adriaan A Voors; Christiane E Angermann; John R Teerlink; Sean P Collins; Mikhail Kosiborod; Jan Biegus; João Pedro Ferreira; Michael E Nassif; Mitchell A Psotka; Jasper Tromp; C Jan Willem Borleffs; Changsheng Ma; Joseph Comin-Colet; Michael Fu; Stefan P Janssens; Robert G Kiss; Robert J Mentz; Yasushi Sakata; Henrik Schirmer; Morten Schou; P Christian Schulze; Lenka Spinarova; Maurizio Volterrani; Jerzy K Wranicz; Uwe Zeymer; Shelley Zieroth; Martina Brueckmann; Jonathan P Blatchford; Afshin Salsali; Piotr Ponikowski
Journal:  Nat Med       Date:  2022-02-28       Impact factor: 53.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.